Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Gains from Sales and Divestitures (2018 - 2022)

Kiora Pharmaceuticals (KPRX) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $246.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Gains from Sales and Divestitures fell 5.38% year-over-year to $246.0, compared with a TTM value of $246.0 through Sep 2022, down 5.38%, and an annual FY2021 reading of $46437.0, up 2.25% over the prior year.
  • Gains from Sales and Divestitures was $246.0 for Q3 2022 at Kiora Pharmaceuticals, down from $9781.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $447961.0 in Q4 2019 and bottomed at $246.0 in Q3 2022.
  • Average Gains from Sales and Divestitures over 5 years is $51081.7, with a median of $10099.0 recorded in 2021.
  • The sharpest move saw Gains from Sales and Divestitures surged 10689.04% in 2019, then crashed 98.91% in 2021.
  • Year by year, Gains from Sales and Divestitures stood at $4152.0 in 2018, then soared by 10689.04% to $447961.0 in 2019, then tumbled by 89.86% to $45417.0 in 2020, then increased by 2.25% to $46437.0 in 2021, then tumbled by 99.47% to $246.0 in 2022.
  • Business Quant data shows Gains from Sales and Divestitures for KPRX at $246.0 in Q3 2022, $9781.0 in Q2 2022, and $9079.0 in Q1 2022.